vs
Side-by-side financial comparison of HUTCHMED (China) Ltd (HCM) and Ralliant Corp (RAL). Click either name above to swap in a different company.
Ralliant Corp is the larger business by last-quarter revenue ($529.1M vs $270.8M, roughly 2.0× HUTCHMED (China) Ltd). Ralliant Corp runs the higher net margin — 7.5% vs 0.7%, a 6.8% gap on every dollar of revenue. On growth, Ralliant Corp posted the faster year-over-year revenue change (-0.5% vs -16.5%). Ralliant Corp produced more free cash flow last quarter ($126.6M vs $3.4M).
HUTCHMED (China) LtdHCMEarnings & Financial Report
HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.
HCM vs RAL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.8M | $529.1M |
| Net Profit | $2.0M | $39.9M |
| Gross Margin | 37.7% | 50.8% |
| Operating Margin | -13.2% | 9.8% |
| Net Margin | 0.7% | 7.5% |
| Revenue YoY | -16.5% | -0.5% |
| Net Profit YoY | -83.6% | -56.1% |
| EPS (diluted) | $0.00 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.8M | — | ||
| Q3 25 | — | $529.1M | ||
| Q2 25 | $277.7M | $503.3M | ||
| Q1 25 | $324.5M | — | ||
| Q3 24 | — | $531.7M | ||
| Q2 24 | $305.7M | $533.7M | ||
| Q2 23 | $532.9M | — | ||
| Q2 22 | $202.0M | — |
| Q4 25 | $2.0M | — | ||
| Q3 25 | — | $39.9M | ||
| Q2 25 | $455.0M | $47.6M | ||
| Q1 25 | $11.9M | — | ||
| Q3 24 | — | $90.9M | ||
| Q2 24 | $25.8M | $64.8M | ||
| Q2 23 | $168.6M | — | ||
| Q2 22 | $-162.9M | — |
| Q4 25 | 37.7% | — | ||
| Q3 25 | — | 50.8% | ||
| Q2 25 | 0.1% | 49.3% | ||
| Q1 25 | 48.0% | — | ||
| Q3 24 | — | 52.6% | ||
| Q2 24 | 41.1% | 51.5% | ||
| Q2 23 | 0.0% | — | ||
| Q2 22 | 0.1% | — |
| Q4 25 | -13.2% | — | ||
| Q3 25 | — | 9.8% | ||
| Q2 25 | -1.3% | 11.7% | ||
| Q1 25 | -5.0% | — | ||
| Q3 24 | — | 20.9% | ||
| Q2 24 | -9.0% | 19.7% | ||
| Q2 23 | 21.0% | — | ||
| Q2 22 | -97.4% | — |
| Q4 25 | 0.7% | — | ||
| Q3 25 | — | 7.5% | ||
| Q2 25 | 163.8% | 9.5% | ||
| Q1 25 | 3.7% | — | ||
| Q3 24 | — | 17.1% | ||
| Q2 24 | 8.4% | 12.1% | ||
| Q2 23 | 31.6% | — | ||
| Q2 22 | -80.6% | — |
| Q4 25 | $0.00 | — | ||
| Q3 25 | — | $0.35 | ||
| Q2 25 | $0.52 | $0.42 | ||
| Q1 25 | $0.01 | — | ||
| Q3 24 | — | $0.81 | ||
| Q2 24 | $0.03 | $0.57 | ||
| Q2 23 | $0.19 | — | ||
| Q2 22 | $-0.19 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $264.2M |
| Total DebtLower is stronger | $93.2M | $1.1B |
| Stockholders' EquityBook value | $1.2B | $3.0B |
| Total Assets | $1.8B | $5.3B |
| Debt / EquityLower = less leverage | 0.08× | 0.39× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | — | ||
| Q3 25 | — | $264.2M | ||
| Q2 25 | $1.4B | $198.6M | ||
| Q1 25 | $836.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $802.5M | — | ||
| Q2 23 | $856.2M | — | ||
| Q2 22 | $826.2M | — |
| Q4 25 | $93.2M | — | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | $93.4M | $1.1B | ||
| Q1 25 | $82.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $82.1M | — | ||
| Q2 23 | $40.1M | — | ||
| Q2 22 | $418.0K | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | — | $3.0B | ||
| Q2 25 | $1.2B | $3.0B | ||
| Q1 25 | $759.9M | — | ||
| Q3 24 | — | $4.0B | ||
| Q2 24 | $740.1M | $4.0B | ||
| Q2 23 | $782.0M | — | ||
| Q2 22 | $799.7M | — |
| Q4 25 | $1.8B | — | ||
| Q3 25 | — | $5.3B | ||
| Q2 25 | $1.8B | $5.2B | ||
| Q1 25 | $1.3B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.3B | — | ||
| Q2 23 | $1.3B | — | ||
| Q2 22 | $1.2B | — |
| Q4 25 | 0.08× | — | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | 0.08× | 0.38× | ||
| Q1 25 | 0.11× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.11× | — | ||
| Q2 23 | 0.05× | — | ||
| Q2 22 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.2M | $138.6M |
| Free Cash FlowOCF − Capex | $3.4M | $126.6M |
| FCF MarginFCF / Revenue | 1.2% | 23.9% |
| Capex IntensityCapex / Revenue | 1.8% | 2.3% |
| Cash ConversionOCF / Net Profit | 4.21× | 3.47× |
| TTM Free Cash FlowTrailing 4 quarters | $-96.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.2M | — | ||
| Q3 25 | — | $138.6M | ||
| Q2 25 | $-72.9M | — | ||
| Q1 25 | $40.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-39.8M | — | ||
| Q2 23 | $226.4M | — | ||
| Q2 22 | $-89.9M | — |
| Q4 25 | $3.4M | — | ||
| Q3 25 | — | $126.6M | ||
| Q2 25 | $-82.2M | — | ||
| Q1 25 | $32.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-49.9M | — | ||
| Q2 23 | $202.0M | — | ||
| Q2 22 | $-105.6M | — |
| Q4 25 | 1.2% | — | ||
| Q3 25 | — | 23.9% | ||
| Q2 25 | -29.6% | — | ||
| Q1 25 | 10.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -16.3% | — | ||
| Q2 23 | 37.9% | — | ||
| Q2 22 | -52.3% | — |
| Q4 25 | 1.8% | — | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | 3.3% | — | ||
| Q1 25 | 2.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.3% | — | ||
| Q2 23 | 4.6% | — | ||
| Q2 22 | 7.8% | — |
| Q4 25 | 4.21× | — | ||
| Q3 25 | — | 3.47× | ||
| Q2 25 | -0.16× | — | ||
| Q1 25 | 3.38× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.54× | — | ||
| Q2 23 | 1.34× | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HCM
Segment breakdown not available.
RAL
| Industrial Manufacturing | $111.1M | 21% |
| Defense And Space | $93.6M | 18% |
| Diversified Electronics | $91.0M | 17% |
| Test And Measurement | $76.8M | 15% |
| Communications | $60.7M | 11% |
| Semiconductors | $51.4M | 10% |
| Other Direct End Markets | $44.4M | 8% |
